Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers

C. Ferri, D. Giuggioli, A. Manfredi, N. Quirici, C. Scavullo, M. Colaci, U. Gianelli, G. Lambertenghi Deliliers, N. Del Papa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Systemic sclerosis (SSc) is often complicated by severe skin ulcers that are unresponsive to traditional treatments. Vascular alterations are responsible for the ischaemic features of the disease in both the skin and visceral organs. Defective neoangiogenesis correlates with an abnormally reduced quantity of circulating endothelial progenitor cells (EPCs) caused by impaired maturation potential and proliferative capacity of bone-marrow endothelial stem cells. We report a patient with nonhealing cutaneous ulcers successfully treated with recombinant human erythropoietin (rHuEPO). The possible biological effects of this drug were also investigated. Before rHuEPO treatment, the bone-marrow sample contained reduced numbers of EPCs, which were functionally impaired. After a 6-month rHuEPO cycle, a marked increase in endothelial progenitor markers was seen, along with a significant reduction in their apoptotic rates. The clinical and laboratory data variations before and after rHuEPO treatment give new insights into the pathogenetic role of impaired endothelial stem-cell maturation and defective neoangiogenesis in patients with SSc.

Original languageEnglish
Pages (from-to)885-887
Number of pages3
JournalClinical and Experimental Dermatology
Volume35
Issue number8
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Skin Ulcer
Systemic Scleroderma
Erythropoietin
Wound Healing
Stem Cells
Endothelial Cells
Bone Marrow Cells
Blood Vessels
Therapeutics
Bone Marrow
Skin
Pharmaceutical Preparations
Endothelial Progenitor Cells

ASJC Scopus subject areas

  • Dermatology

Cite this

Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers. / Ferri, C.; Giuggioli, D.; Manfredi, A.; Quirici, N.; Scavullo, C.; Colaci, M.; Gianelli, U.; Lambertenghi Deliliers, G.; Del Papa, N.

In: Clinical and Experimental Dermatology, Vol. 35, No. 8, 12.2010, p. 885-887.

Research output: Contribution to journalArticle

Ferri, C. ; Giuggioli, D. ; Manfredi, A. ; Quirici, N. ; Scavullo, C. ; Colaci, M. ; Gianelli, U. ; Lambertenghi Deliliers, G. ; Del Papa, N. / Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers. In: Clinical and Experimental Dermatology. 2010 ; Vol. 35, No. 8. pp. 885-887.
@article{021725c6fbcd45c99adb6188b6f16624,
title = "Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers",
abstract = "Systemic sclerosis (SSc) is often complicated by severe skin ulcers that are unresponsive to traditional treatments. Vascular alterations are responsible for the ischaemic features of the disease in both the skin and visceral organs. Defective neoangiogenesis correlates with an abnormally reduced quantity of circulating endothelial progenitor cells (EPCs) caused by impaired maturation potential and proliferative capacity of bone-marrow endothelial stem cells. We report a patient with nonhealing cutaneous ulcers successfully treated with recombinant human erythropoietin (rHuEPO). The possible biological effects of this drug were also investigated. Before rHuEPO treatment, the bone-marrow sample contained reduced numbers of EPCs, which were functionally impaired. After a 6-month rHuEPO cycle, a marked increase in endothelial progenitor markers was seen, along with a significant reduction in their apoptotic rates. The clinical and laboratory data variations before and after rHuEPO treatment give new insights into the pathogenetic role of impaired endothelial stem-cell maturation and defective neoangiogenesis in patients with SSc.",
author = "C. Ferri and D. Giuggioli and A. Manfredi and N. Quirici and C. Scavullo and M. Colaci and U. Gianelli and {Lambertenghi Deliliers}, G. and {Del Papa}, N.",
year = "2010",
month = "12",
doi = "10.1111/j.1365-2230.2010.03847.x",
language = "English",
volume = "35",
pages = "885--887",
journal = "Clinical and Experimental Dermatology",
issn = "0307-6938",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers

AU - Ferri, C.

AU - Giuggioli, D.

AU - Manfredi, A.

AU - Quirici, N.

AU - Scavullo, C.

AU - Colaci, M.

AU - Gianelli, U.

AU - Lambertenghi Deliliers, G.

AU - Del Papa, N.

PY - 2010/12

Y1 - 2010/12

N2 - Systemic sclerosis (SSc) is often complicated by severe skin ulcers that are unresponsive to traditional treatments. Vascular alterations are responsible for the ischaemic features of the disease in both the skin and visceral organs. Defective neoangiogenesis correlates with an abnormally reduced quantity of circulating endothelial progenitor cells (EPCs) caused by impaired maturation potential and proliferative capacity of bone-marrow endothelial stem cells. We report a patient with nonhealing cutaneous ulcers successfully treated with recombinant human erythropoietin (rHuEPO). The possible biological effects of this drug were also investigated. Before rHuEPO treatment, the bone-marrow sample contained reduced numbers of EPCs, which were functionally impaired. After a 6-month rHuEPO cycle, a marked increase in endothelial progenitor markers was seen, along with a significant reduction in their apoptotic rates. The clinical and laboratory data variations before and after rHuEPO treatment give new insights into the pathogenetic role of impaired endothelial stem-cell maturation and defective neoangiogenesis in patients with SSc.

AB - Systemic sclerosis (SSc) is often complicated by severe skin ulcers that are unresponsive to traditional treatments. Vascular alterations are responsible for the ischaemic features of the disease in both the skin and visceral organs. Defective neoangiogenesis correlates with an abnormally reduced quantity of circulating endothelial progenitor cells (EPCs) caused by impaired maturation potential and proliferative capacity of bone-marrow endothelial stem cells. We report a patient with nonhealing cutaneous ulcers successfully treated with recombinant human erythropoietin (rHuEPO). The possible biological effects of this drug were also investigated. Before rHuEPO treatment, the bone-marrow sample contained reduced numbers of EPCs, which were functionally impaired. After a 6-month rHuEPO cycle, a marked increase in endothelial progenitor markers was seen, along with a significant reduction in their apoptotic rates. The clinical and laboratory data variations before and after rHuEPO treatment give new insights into the pathogenetic role of impaired endothelial stem-cell maturation and defective neoangiogenesis in patients with SSc.

UR - http://www.scopus.com/inward/record.url?scp=78149362868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149362868&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2230.2010.03847.x

DO - 10.1111/j.1365-2230.2010.03847.x

M3 - Article

C2 - 20456380

AN - SCOPUS:78149362868

VL - 35

SP - 885

EP - 887

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

IS - 8

ER -